Jacqueline Bernard, MD
Neurology · Portland, ORNPI 1710924709
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,971 of the $17,371 with a category attached, or 86.2%. 6 manufacturers reported payments, led by TG Therapeutics, Inc. at 47.8% of the total. Reporting peaked in 2020 at $7,767 and has fallen 61.7% since, to $2,972 in 2025. Among neurology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $827.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$8K
- Biogen$7K
- Amgen$1K
- AstraZeneca$1K
- AbbVie$25
- Regeneron Healthcare Solutions, Inc.$19
What the payments were for
- Consulting fees$14,97186%
- Speaking & faculty fees$1,2507%
- Travel & lodging$6244%
- Food & beverage$5263%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 10 | $8,309 |
| Biogen | 7 | $6,747 |
| Amgen | 1 | $1,250 |
| AstraZeneca | 1 | $1,020 |
| AbbVie | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,371 in reported general payments places this provider in the 90th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 35 | $326,002 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 37 | $323,820 |
| CopaxoneGlatiramer Acetate | 51 | $302,906 |
| Glatiramer Acetate | 22 | $40,096 |
| Nurtec OdtRimegepant Sulfate | 20 | $25,012 |
| Aimovig AutoinjectorErenumab-Aooe | 30 | $21,675 |
| GlatopaGlatiramer Acetate | 11 | $17,939 |
| Dimethyl Fumarate | 56 | $8,295 |
| Emgality PenGalcanezumab-Gnlm | 11 | $8,182 |
| Baclofen | 227 | $7,621 |
| Dalfampridine ErDalfampridine | 50 | $6,553 |
| Lacosamide | 12 | $5,852 |
| Gabapentin | 239 | $3,967 |
| Duloxetine Hcl | 48 | $1,813 |
| Modafinil | 23 | $1,566 |
Paid to pharmacies, not to this prescriber.
Other neurology in Portland
- Kyle SmootPortland$932K
- Chafic KaramPortland$727K
- Herbert KrobPortland$416K
- Stanley CohanPortland$334K
- Matthew BrodskyPortland$123K
- Delaram SafarpourPortland$77K
- Kiren Kresa-ReahlPortland$71K
- Nizar ChahinPortland$57K
- Jeffrey KayePortland$54K
- Michelle CameronPortland$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.